During the Trading Day
|2.37|| -0.03 / -1.25%|
As of 4:02pm ET
|2.37|| 0.00 / 0.00%|
CorMedix, Inc. operates as pharmaceutical and medical device company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, specifically in the dialysis and non-dialysis areas. The company's products are Neutrolin CRMD003, Thixotropic Gel CRMD004, Deferiprone CRMD001 and Urine Catalytic Test CRMD002. CorMedix was founded on July 28, 2006 and is headquartered in Bridgewater, NJ.
|Randy D. Milby||CEO, Director & Head-Investor Relations|
|Antony E. Pfaffle||Secretary, Chief Scientific Officer & Director|